Navigation Links
MicroRNA molecule found to be a potent tumor-suppressor in lung cancer
Date:9/16/2013

COLUMBUS, Ohio New research shows that microRNA-486 is a potent tumor-suppressor molecule in lung cancer, and that the it helps regulate the proliferation and migration of lung-cancer cells, and the induction of programmed cell death, or apoptosis, in those cells.

The preclinical study was led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James). It found that microRNA-486 (miR-486) directly targets the insulin growth-factor pathway, which is important for cell survival and proliferation. Alternations in the pathway are believed to play an early role in tumor initiation and progression.

The researchers further found that miR-486 is itself regulated by the tumor-suppressor gene p53, the most frequently altered gene in human cancers, and that activity of miR-486 is partially dependent upon functional p53.

Published in the Proceedings of the National Academy of Sciences, the study suggests that miR-486 might serve as a biomarker for lung-cancer patients who might respond to treatment with insulin-growth-factor inhibitors.

"It wasn't known whether miR-486 functioned as an oncogene or a tumor-suppressor gene in lung cancer," says co-corresponding author Patrick Nana-Sinkam, MD, associate professor of medicine and a researcher with the OSUCCC James Molecular Biology and Cancer Genetics Program.

"miR-486 appears to be a biomarker for lung cancer, but its mechanisms of action remain unclear," he says. "These findings show that miR-486 serves a tumor-suppressor function in lung cancer, and that miR-486 action is partially dependent on p53."

"This partial reliance of one tumor-suppressor on another was a surprise," says principal investigator and co-corresponding author Carlo M. Croce, MD, director of Ohio State's Human Cancer Genetics program and the John W. Wolfe Chair in Human Cancer Genetics at the OSUCCC James. "We don't know yet what implications, if any, this might have for the development of targeted therapies."

MicroRNAs are a class of short, non-coding RNAs that regulate the translation or degradation of messenger RNA and therefore the proteins that cells make. Research is showing that certain microRNAs are frequently dysregulated in cancer.

Nana-Sinkam and his colleagues examined lung-tumor samples from 81 patients with stage-1 nonsmall-cell lung cancer and tumor-cell lines. Analyses identified miR-486 as the most decreased of microRNAs in the cells, so the researchers chose it for further investigation.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center
Source:Eurekalert

Related biology news :

1. MicroRNA controls malignancy and resistance of breast cancer cells
2. Its a trap! New laboratory technique captures microRNA targets
3. MicroRNAs in plants: Regulation of the regulator
4. MicroRNA-218 targets medulloblastoma, most aggressive childhood brain cancer
5. MicroRNAs present exciting opportunities for cancer therapy and diagnosis
6. Triple-negative breast cancer subtypes identified using microRNA
7. Study: MicroRNA cooperation mutes breast cancer oncogenes
8. MicroRNAs have diagnostic and prognostic potential in urinary bladder cancer
9. Biomarkers Market: Epigenetic & MicroRNA Biomarkers Report
10. BIDMC cardiovascular institute researchers will lead $4 million NIH grant to study micrornas
11. Droplet Digital PCR enables reproducible quantification of microRNA biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/11/2016)... March 11, 2016 --> ... research report "Image Recognition Market by Technology (Pattern Recognition), ... Advertising), by Deployment Type (On-Premises and Cloud), by Industry ... published by MarketsandMarkets, the global market is expected to ... 29.98 Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
(Date:3/9/2016)... -- Nigeria . Recently, the ... public service employees either did not exist with their ...    --> Nigeria . Recently, ... 23,000 public service employees either did not exist with ... unlawfully.    --> DERMALOG, the biometrics innovation ...
Breaking Biology News(10 mins):
(Date:5/23/2016)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... Directors has approved the payment of a quarterly cash dividend ... The cash dividend of $0.24 per share will be ... record as of the close of business on June 24, ... the Board of Directors and may be adjusted as business ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, ... new way to treat the disease. Surviving Mesothelioma has just posted an article on ... several Korean institutions based their mesothelioma study on the fact the Manumycin A, a ...
(Date:5/19/2016)... There is no saying when ... relentless pressures in pricing and lack in consumer confidence. ... though - numerous opportunities are up for grabs but ... presents four names in this sector: Portola Pharmaceuticals Inc. ... VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
Breaking Biology Technology: